Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
- PMID: 38477511
- PMCID: PMC10935883
- DOI: 10.1002/cam4.7075
Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
Abstract
Purpose: A pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) is seen in up to 40% of the patients with esophageal squamous cell carcinoma (ESCC). No nomogram has been constructed for the prediction of pCR for patients whose primary chemotherapy was a taxane-based regimen. The aim is to identify characteristics associated with a pCR through analyzing multiple pre- and post-nCRT variables and to develop a nomogram for the prediction of pCR for these patients by integrating clinicopathological characteristics and hematological biomarkers.
Materials and methods: We analyzed 293 patients with ESCC who underwent nCRT followed by esophagectomy. Clinicopathological factors, hematological parameters before nCRT, and hematotoxicity during nCRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and evaluated for both discrimination and calibration.
Results: After surgery, 37.88% of the study patients achieved pCR. Six variables were included in the nomogram: sex, cN stage, chemotherapy regimen, duration of nCRT, pre-nCRT neutrophil-to-lymphocyte ratio (NLR), and pre-nCRT platelet-to-lymphocyte ratio (PLR). The nomogram indicated good accuracy and consistency in predicting pCR, with a C-index of 0.743 (95% confidence interval: 0.686, 0.800) and a p value of 0.600 (>0.05) in the Hosmer-Lemeshow goodness-of-fit test.
Conclusions: Female, earlier cN stage, duration of nCRT (< 62 days), chemotherapy regimen of taxane plus platinum, pre-nCRT NLR (≥2.199), and pre-nCRT PLR (≥99.302) were significantly associated with a higher pCR in ESCC patients whose primary chemotherapy was a taxane-based regimen for nCRT. A nomogram was developed and internally validated, showing good accuracy and consistency.
Keywords: esophageal squamous cell carcinoma; neoadjuvant chemoradiotherapy; nomogram; pathologic complete response.
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.Cancer Res Treat. 2021 Jan;53(1):172-183. doi: 10.4143/crt.2020.594. Epub 2020 Sep 4. Cancer Res Treat. 2021. PMID: 32898941 Free PMC article.
-
Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12519. Dis Esophagus. 2017. PMID: 27868287
-
CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.J Transl Med. 2024 Jun 18;22(1):579. doi: 10.1186/s12967-024-05392-4. J Transl Med. 2024. PMID: 38890720 Free PMC article.
-
Predicting anastomotic leak in patients with esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy using a nomogram based on CT radiomic and clinicopathologic factors.BMC Cancer. 2025 Mar 15;25(1):484. doi: 10.1186/s12885-025-13884-9. BMC Cancer. 2025. PMID: 40089723 Free PMC article.
-
Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis.Cancer Med. 2024 Feb;13(4):e7076. doi: 10.1002/cam4.7076. Cancer Med. 2024. PMID: 38457244 Free PMC article.
Cited by
-
Efficacy and prognosis biomarker of locally advanced ESCC patients treated with neoadjuvant chemotherapy and anti-PD-1 immunotherapy.Front Oncol. 2025 Feb 19;14:1498675. doi: 10.3389/fonc.2024.1498675. eCollection 2024. Front Oncol. 2025. PMID: 40046668 Free PMC article.
References
-
- Shah MA, Altorki N, Patel P, Harrison S, Bass A, Abrams JA. Improving outcomes in patients with oesophageal cancer. Nat Rev Clin Oncol. 2023;20(6):390‐407. - PubMed
-
- van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative Chemoradiotherapy for esophageal or junctional. Cancer. 2012;366(22):2074‐2084. - PubMed
-
- Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330‐4337. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical